In landing an FDA approval for its highly anticipated respiratory syncytial virus (RSV) vaccine, GSK has both beat out its market rivals and initiated its next major...

As Horizon works to close its $28 billion sale to California biotech giant Amgen, the company's first-quarter financial results show some weakness compared with a ye...

ImmunoGen has shaken off a previous phase 3 flop for its ovarian cancer antibody-drug conjugate Elahere with what its CEO is calling a “home run” trial success. ...

The battle between the makers of face-filling beauty products is getting ugly. Now, AbbVie is throwing a new wrinkle into the mix. The pharma giant is accusing Re...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secon...

In a surprise announcement Wednesday, Bristol Myers Squibb said its CEO Giovanni Caforio, M.D., will end his eight-year tenure and hand the baton to Chief Commercial...

There are many over-the-counter probiotic food additions that one can eat, and now the FDA has approved the first oral microbiome to be used as a therapeutic. The...

After declaring bankruptcy two months ago and closing all production sites, Akorn is yanking its products from the market. Akorn on Wednesday put out a voluntary ...

AstraZeneca and Merck & Co.’s Lynparza may have claimed a broad trial success—and European approval—in prostate cancer, but the FDA has its reservations. In b...